ACOs Get In Gear, Accelerating Biopharma’s Value Imperative

Pharmaceutical companies have been reluctant to discuss their accountable care organization strategies, but the 32 “Pioneer” ACOs created this year could impact the way pharma develops and commercializes its drugs, and their influence will be felt well beyond their current Medicare remit.

For any biopharma manufacturers standing on the sidelines as Medicare accountable care organizations take shape, the time has arrived to get involved.

The first group of ACOs began operations January 1. From day one, their focus is on improving patient outcomes while also reducing the growth of health care costs. Manufacturers that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo